Structured evidence table for Saffron Skin Aging Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Saffron Skin Aging Randomized Trial | Clinical evidence supports the efficacy of ceramide-dominant formulations in improving hydration and reducing transepidermal water loss (TEWL), with studies reporting TEWL reductions of approximately 10% and hydration improvement lasting up to 72 hours. | 4 | De A (2026) | Oryza Ceramax in Dermatologic Care: A Multi-pathway Approach to Skin Hydration and Barrier Repair. |
| Saffron Skin Aging Randomized Trial | Its formulation characteristics are consistent with evidence-based principles for skin barrier protection and hydration maintenance. | 4 | De A (2026) | Oryza Ceramax in Dermatologic Care: A Multi-pathway Approach to Skin Hydration and Barrier Repair. |
| Saffron Skin Aging Randomized Trial | Environmental stressors, including climate change, pollution, and lifestyle factors, can disrupt the skin barrier, leading to dryness and exacerbating conditions such as atopic dermatitis (AD), acne, and psoriasis. | 4 | De A (2026) | Oryza Ceramax in Dermatologic Care: A Multi-pathway Approach to Skin Hydration and Barrier Repair. |
| Saffron Skin Aging Randomized Trial | Effective barrier repair requires maintaining hydration and lipid balance, particularly the ceramide-cholesterol-fatty acid ratio of 3:1:1, which is recommended by dermatological societies for optimal skin restoration. | 4 | De A (2026) | Oryza Ceramax in Dermatologic Care: A Multi-pathway Approach to Skin Hydration and Barrier Repair. |
| Saffron Skin Aging Randomized Trial | Age-related physiological changes and increased sensitivity to side effects often limit the use of conventional medications in this population. | 4 | Kim CE (2025) | Integrating clinical evidence with natural product therapies for elderly-onset type 2 diabetes. |
| Saffron Skin Aging Randomized Trial | These findings not only provide mechanistic insights into the role of natural bioactive compounds in diabetes management but also highlight their clinical relevance, suggesting potential applications as adjunctive therapies for elderly individuals with limited pharmacological tolerance, and guiding future research toward evidence-based integration of such agents into clinical practice. | 4 | Kim CE (2025) | Integrating clinical evidence with natural product therapies for elderly-onset type 2 diabetes. |
| Saffron Skin Aging Randomized Trial | Elderly-onset type 2 diabetes presents a distinct clinical profile, typically characterized by milder hyperglycemia and specific risks for complications. | 4 | Kim CE (2025) | Integrating clinical evidence with natural product therapies for elderly-onset type 2 diabetes. |
Source documents